Q3 2023 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2023-11-14 · accession 0001892134-23-000001
$1.51B
Reported value
52
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $204.5M | 13.6% | 6,470,392 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $131.6M | 8.74% | 9,781,472 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $114.7M | 7.62% | 988,460 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $112.2M | 7.45% | 12,131,705 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $104.8M | 6.96% | 10,109,279 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $71.9M | 4.77% | 2,725,949 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $59.4M | 3.94% | 1,164,405 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $54.4M | 3.61% | 2,371,304 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $49.1M | 3.26% | 3,014,349 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $47.3M | 3.14% | 1,589,931 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $46.1M | 3.06% | 8,684,232 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $34.2M | 2.27% | 2,985,757 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $31.8M | 2.11% | 1,787,527 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $31.2M | 2.07% | 3,238,859 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $30.8M | 2.04% | 655,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $28.7M | 1.91% | 1,403,013 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $27.6M | 1.83% | 997,455 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $23.4M | 1.55% | 614,043 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $22.3M | 1.48% | 1,388,889 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $17.6M | 1.17% | 746,479 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $16.4M | 1.09% | 1,204,867 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $16.2M | 1.07% | 899,700 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $15.1M | 1.00% | 4,000,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $15.0M | 1.00% | 6,881,090 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $14.6M | 0.97% | 1,501,383 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $14.3M | 0.95% | 1,050,483 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $14.2M | 0.94% | 1,028,013 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $13.7M | 0.91% | 464,937 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $13.1M | 0.87% | 630,897 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $13.0M | 0.86% | 2,142,855 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $8.7M | 0.58% | 3,746,857 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $8.7M | 0.58% | 600,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $8.7M | 0.58% | 881,173 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $8.6M | 0.57% | 393,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $8.5M | 0.57% | 400,000 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $8.4M | 0.56% | 1,803,204 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $7.2M | 0.48% | 292,002 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $6.6M | 0.44% | 386,762 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $6.4M | 0.43% | 203,684 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $6.2M | 0.41% | 127,900 | Common | SOLE |
| 88369M101 | — | THESEUS PHARMACEUTICALS INC | $6.0M | 0.40% | 2,248,194 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $5.6M | 0.37% | 285,331 | Common | SOLE |
| 09609G100 | — | BLUEBIRD BIO INC | $5.2M | 0.35% | 1,709,907 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $4.9M | 0.32% | 849,022 | Common | SOLE |
| 24344T101 | DCPHEUR | DECIPHERA PHARMACEUTICALS IN | $4.7M | 0.31% | 370,000 | Common | SOLE |
| 869367102 | — | SUTRO BIOPHARMA INC | $2.7M | 0.18% | 780,000 | Common | SOLE |
| 39868T105 | 2JQ | GRITSTONE BIO INC | $2.5M | 0.16% | 1,430,878 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $1.8M | 0.12% | 264,377 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $1.6M | 0.10% | 600,000 | PUT | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $1.5M | 0.10% | 1,647,030 | Common | SOLE |
| 702712100 | — | PASSAGE BIO INC | $1.2M | 0.08% | 1,758,219 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $950,633 | 0.06% | 500,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.